Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17 janv. 2025 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
12 janv. 2025 11h00 HE
|
Ultragenyx Pharmaceutical Inc.
Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to $89...
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
06 janv. 2025 02h00 HE
|
Ultragenyx Pharmaceutical Inc.
BASEL, Switzerland, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 déc. 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)
20 déc. 2024 03h00 HE
|
Ultragenyx Pharmaceutical Inc.
INTENDED FOR USE WITH MEDICAL MEDIA IN THE UK ONLYLONDON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and...
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
19 déc. 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study...
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
19 déc. 2024 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...
Ultragenyx to Participate in Investor Conferences in December
26 nov. 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 nov. 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...